Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Заявленная компания
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions читать еще
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
Что самое позитивное вы можете сказать о культуре и обстановке на вашей работе?
The excitement associated with the expanded use of XPOVIO.
Что приносит вам больше всего счастья/радости на работе?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Other Employee Reviews for Karyopharm Therapeutics
×